Medifast Valuation
Is MED * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MED * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MED * (MX$507.81) is trading above our estimate of fair value (MX$295.89)
Significantly Below Fair Value: MED * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MED *?
Other financial metrics that can be useful for relative valuation.
What is MED *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$294.44m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.2x |
Enterprise Value/EBITDA | 1.7x |
PEG Ratio | -0.06x |
Price to Earnings Ratio vs Peers
How does MED *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 38.5x | ||
NATR Nature's Sunshine Products | 24.3x | 10.8% | US$366.0m |
4917 Mandom | 35.1x | 24.5% | JP¥58.5b |
533229 Bajaj Consumer Care | 21.5x | 11.6% | ₹34.4b |
530843 Cupid | 73.2x | n/a | ₹29.2b |
MED * Medifast | 4.3x | -75.9% | Mex$294.4m |
Price-To-Earnings vs Peers: MED * is good value based on its Price-To-Earnings Ratio (4.3x) compared to the peer average (38.5x).
Price to Earnings Ratio vs Industry
How does MED *'s PE Ratio compare vs other companies in the Global Personal Products Industry?
Price-To-Earnings vs Industry: MED * is good value based on its Price-To-Earnings Ratio (4.3x) compared to the Global Personal Products industry average (24.7x).
Price to Earnings Ratio vs Fair Ratio
What is MED *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 4.3x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MED *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.